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Epidemiological data clearly indicate a strong link between obesity, metabolic disorders and cardiovascular (CV)
risk factors. Their clustering (usually referred to as metabolic syndrome [MetS]) synergistically acts in conferring
an overall CV risk higher than that of each single condition [1]. Despite this evidence, the pathophysiology of MetS
still represents a challenge for both scientists and clinicians, as even the role of adipose tissue (AT) is currently
questioning. Alongside with the unequivocal link between obesity (as measured by body mass index [BMI]) and
increased mortality in the general population, clinical studies in patients with established CVD have paradoxically
reported a better outcome in obese individuals [2]. Indeed, the use of BMI per se does not truly consider body fat
composition/distribution and then it cannot support pathophysiological relevance of epidemiological observations.
Therefore, the paradoxical association between high BMI and better CV outcome, usually referred to as ‘obesity
paradox’ should be actually considered as a ‘BMI paradox’ [2]. When indexes of abdominal adiposity are used, this
paradox disappears: waist circumference and waist-to-hip ratio are indeed linearly associated with increased CV
mortality risk [3]. Although genetic variables have a causal role in developing central obesity and related metabolic
complications, there is still no explanation for their contribution to molecular and clinical features of MetS, as for
their variation across ethnicity and gender [4]. Volumetric studies and secretome analysis are increasingly clarifying
how body fat depots contribute to MetS and CV risk through a multitude of dysregulated pathways involving
adipogenesis, adipocytokine balance, oxidative stress, lipolysis and inflammation [5–8]. Concerning the latter, the
most of the studies focused on infiltrating macrophages and their related mediators. Especially CRP has been widely
reported as the classical paradigm of inflammatory biomarker associated with atherosclerotic CV disease.
Several studies also linked CRP with abdominal adiposity and other clinical features of MetS [9]. In line with this,
many researches attempted at including serum hs-CRP as additional diagnostic criterion for MetS diagnosis [10].
Nevertheless, its molecular implication in MetS has not yet been elucidated so that neither hs-CRP nor other
inflammatory biomarkers are considered as diagnostic criteria by any guideline. Among them, the expression of
osteopontin (OPN) was shown to dramatically increase in the AT of obese patients, where promoted adipocyte
dysfunction at several levels: impaired pre-adipocyte maturation [11], aromatase expression with estradiol produc-
tion [12] and even a osseous differentiation of fat tissue [13]. Far from having only a local effect, visceral fat-derived
OPN displays a role in promoting hepatic steatosis and cardiac aging through mechanisms involving matrix re-
modeling, fibrosis and oxidative stress [14–16]. Further supporting an active role in obesity and MetS, OPN was
also shown to correlate with clinical response to diet and bariatric surgery [17,18]. Nevertheless, at least two critical
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points about the biological activity of OPN in MetS still remain to be clarified. First, peripheral expression of
OPN still remains poorly investigated. Growing evidence indicates that pro-inflammatory polarized immune cells
accumulate in skeletal muscle where they alter myocyte insulin sensitivity via paracrine or autocrine effects. Even
a direct relationship was not yet confirmed, nonspecific OPN downstream pathways are involved in this process.
Especially the activation of IKK/NF-κB pathway has been described to potentially inhibit downstream insulin
signaling at different levels, including the suppression of GLUT4 expression [19]. Recently, immunohistochemistry
analyses demonstrated that OPN expression was associated to macrophage infiltration in an experimental model of
skeletal muscle injury [20]. Future studies are expected to clarify whether OPN may also have a role in the skeletal
muscle metabolism. To date one only preliminary study has associated serum levels of OPN to the improvement
of peripheral insulin sensitivity in a small cohort of obese diabetic patients undergoing bariatric surgery [18]. In
addition to predict diabetes remission independently duration of disease and weight loss (adjusted OR: 1.05; 95%
CI: 1.01–1.10), serum OPN was also independently associated with the HOMA2-%S, a surrogate measure of
peripheral insulin sensitivity (β = 0.738; p < 0.001). As a second point, the biological activity of OPN in MetS
have been so far limited to macrophage proliferation and polarization [21,22], thus forgetting the strong chemotactic
activity toward neutrophils. Therefore, while the fingerprints of MetS on neutrophil metabolomic profile have
been demonstrated [23], neutrophils are still considered mere effector cells with no direct involvement role in
MetS pathophysiology. Only recently macrophage-released OPN has been associated with neutrophil chemotaxis
nonalcoholic steatohepatitis [24]. Indeed, transplantation of macrophage-depleted visceral AT into lean recipient
mice promoted hepatic macrophage accumulation [24]. As also observed in vitro, this would be due to the enhanced
expression of transmembrane adhesion molecules (i.e., CD11c) in AT macrophages [25]. However, only in the
context of atherosclerotic plaques, a link between OPN, neutrophil recruitment and local injury (i.e., plaque rup-
ture) was demonstrated [26]. Serum OPN was indeed demonstrated to strongly correlate not only with intraplaque
pro-inflammatory M1 macrophage content (r = 0.187; p = 0.009), but especially with the extent on neutrophil
infiltration (r = 0.421; p < 0.001). Far from being a mere observational finding, serum OPN was also demonstrated
to predict plaque rupture and consequent atherothrombotic events independently of age and gender (adjusted HR:
13.1; 95% CI: 2.84–60.78) [26]. Due to the pleiotropic activity, OPN may be then considered a paradigm of the
complex inflammatory processes underlying MetS.
Although it has already been suggested as a CV risk biomarker [27], any potential use in clinical practice shall be
preceded by a further understanding of its biological role. Therefore, despite promising like OPN, the clinical
utility of biomarkers in MetS remains to be validated and cannot be recommended in the daily clinical practice.
Nevertheless, ongoing studies are more in deep exploring inflammatory processes underlying MetS. On the one
hand, there is great attention to identify novel biomarkers of MetS. Among them microRNA (miRNA) have
aroused global interest due to their ubiquitous distribution in metabolic active tissues such as liver, skeletal muscle,
AT and β cells [28]. Many of them are involved in regulating the relevant genes and pathways of main components
of MetS, therefore showing a diagnostic and therapeutic potential. On the other hand, the molecular signals
underlying MetS are constantly under investigation. Especially the epigenetic signature of AT is another intriguing
field of research, being widely influenced by nutrition and microbiota [29], Even though a direct association of
blood leukocyte DNA methylation with adiposity has not yet been demonstrated, hyperglycemia was shown to
upregulate OPN expression by glucose-induced histone acetylation and methylation processes [30]. Finally, it should
take into account that future studies have to carefully consider the analysis of gender differences, which plays a
leading role in metabolically induced inflammation [31]. Although AT distribution across gender influences the
inflammatory response, leukocytes in males are constitutively more prone to be recruited and activated. In line,
we have previously reported how gender difference influences both clinical and inflammatory response to bariatric
surgery [32]. In conclusion, future research should focus on two key points: further validating diagnostic/predictive
values of available and new inflammatory biomarkers, eventually combining them in panel; better understanding
the complex regulatory system underlying inflammatory response in MetS.
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